Drugs / carbocisteine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT01968434 Comparator | Dec 2013 → Mar 2014 | respiratory tract infectious disorder | Clalit Health Services | Completed | No outcome recorded |
| — | NCT03177889 Background | Dec 2021 → Aug 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carbocisteine | “oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]” NCT03177889 ↗ |
| Route | Oral | “oral mucolytics” NCT03177889 ↗ |